Melasma. Chloasma
Conditions
Interventions
Intervention 1: Intralesional Triamcinolone (Hexal Pharmaceutical company) ampul injection Spaced 5 millimeters (the concentration of Triamcinolone is 4 milligrams in milliliter). Intervention 2: Topi
Treatment - Drugs
Intralesional Triamcinolone (Hexal Pharmaceutical company) ampul injection Spaced 5 millimeters (the concentration of Triamcinolone is 4 milligrams in milliliter).
Topical formulation (Cligman cream) containing (Tretinoin 0.1 grams, Dexamethasone 0.1 grams, Hydroquinone 5 grams in a cold cream up to 100 grams) every night one time for two month will be applied o
Sponsors
Vice- chancellor for Research and technology Hamedan University of Medical Science.
Eligibility
Sex/Gender
Female
Age
25 Years to 40 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: (a) patients with melasma; (b) age between 25 and 40. Exclusion criteria: (a) pregnancy; (b) atrophy in melasma lesion; (c) autoimmune disease; (d) male; (e) telangiectasia in melasma lesion; (f) using oral contraceptive
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Color of Melasma lesion. Timepoint: Fifteen and 45 days after injection. Method of measurement: Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Atrophy in Melasma lesion. Timepoint: The first and second months after injections. Method of measurement: Observation of lesion by researcher. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Gholamreza Eshghi
Hamedan University of Medical Science
Outcome results
None listed